Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares climbed Thursday, after the biotechnology company late Wednesday reported a smaller-than-expected Q3 net loss and said enrollment in its Phase 2b ACLF trial has been concluded and dosing has been completed. CNAT was tradubg in a 52-week range of $5.06 to $15.67. Conatus Pharmaceuticals Inc (NASDAQ:CNAT), which isn't yet generating revenue, posted a Q3 net loss applicable to common shareholders of $6.4 million, or $0.42 per share, compared with a year-earlier net loss of $3.3 million, or $0.28 per share. Skewing the year-over-year per-share comparison, there was a 33% jump in the number of shares outstanding. Analysts polled by Capital IQ were expecting a loss of $0.44 per share.The wider loss came as total operating expenses more than doubled to $6.4 million from $3.0 million a year earlier. Research-and-development expenses jumped to $4.4 million from $1.9 million in the year-earlier period. Following the completion of dosing in its Phase 2b ACLF trial, the company said aggregate top-line PK/PD data from the ACLF trial with 21 subjects, the renal impairment trial with 16 subjects, and the hepatic impairment trial with 36 subjects, are expected to be available to the company by year-end 2014 and to be reported publicly "shortly thereafter."The aggregate final data from the three trials "are expected to be sufficient to determine the optimal dosing of emricasan" and will "help determine the future direction for the clinical development of emricasan in potential future studies over a broad range of patient populations, including critically ill patients with varying degrees of liver and kidney function," it added.Click here for a free comprehensive Trend Analysis ReportMondelez International Inc (NASDAQ:MDLZ) on Thursday said it plans to invest $24 million to increase capacity at its confectionery plant in Gebze, Turkey, boosting production at the facility by 20%. The Gebze plant produces local gum, candy and chocolate brands for nearly 50 countries, as well as global brands such as Halls and Trident. Mondelez International Inc (NASDAQ:MDLZ) will add a new production line at the plant, expected to be operational by the end of 2015. The expansion is part of the snack company's ongoing supply-chain reinvention plan, which is expected to deliver $3 billion in gross productivity savings over the next three years. MDLZ shares closed at $37.92 on Wednesday, in a 52-week range of $31.83 to $39.54.Click here for a free comprehensive Trend Analysis ReportZaZa Energy Corporation (NASDAQ:ZAZA), the exploration and production company late Wednesday reported it swung to a Q3 profit as revenue more than doubled on higher production while expenses declined. ZaZa Energy Corporation (NASDAQ:ZAZA) is trading in a 52-week range of $1.66 to $11.50. The company, which has with primary assets in the Eagle Ford and Eagle Ford East resource plays in Texas, late Wednesday posted Q3 net income of $10.1 million, or $0.83 per diluted share, compared with a net loss of $20.6 million, or $2.01 loss per diluted share, in the year-earlier period. Analyst estimates weren't available via Capital IQ. Its Q3 revenue more than doubled $2.7 million, from $1.1 million a year earlier. Production totaled 54.8 million barrels of oil equivalent, a year-over-year increase of 145%. Total operating expenses declined 60%.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
